Bristol Myers Squibb Company $BMY Shares Bought by The Manufacturers Life Insurance Company

Key Points

• The Manufacturers Life Insurance Company increased its Bristol Myers Squibb position by 23.2% in the second quarter, adding 410,243 shares to own 2.18 million shares valued at approximately $125.4 million. Institutional investors collectively own 76.41% of BMY.
• Bristol Myers Squibb reported quarterly EPS of $2.04, exceeding estimates of $1.60, while revenue rose 5.7% year over year to $12.97 billion. The company reaffirmed fiscal 2026 EPS guidance of $6.75–$7.00 and pays a quarterly dividend of $0.63, yielding about 4.0%.
• Investor sentiment is mixed: promising multiple myeloma CAR-T results and pipeline growth support the outlook, but patent-dispute uncertainty, generic competition, elevated put-option activity and cautious analyst views remain concerns. Analysts have a consensus “Moderate Buy” rating with a $66.33 target price.

The Manufacturers Life Insurance Company raised its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 23.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,176,661 shares of the biopharmaceutical company's stock after buying an additional 410,243 shares during the period. The Manufacturers Life Insurance Company owned about 0.11% of Bristol Myers Squibb worth $125,419,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Northwestern Mutual Investment Management Company LLC lifted its position in shares of Bristol Myers Squibb by 0.3% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company's stock worth $3,509,000 after purchasing an additional 172 shares in the last quarter. KCM Investment Advisors LLC grew its holdings in shares of Bristol Myers Squibb by 0.8% in the fourth quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company's stock valued at $1,126,000 after purchasing an additional 174 shares in the last quarter. Sandy Cove Advisors LLC increased its stake in Bristol Myers Squibb by 4.7% during the 2nd quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company's stock worth $227,000 after buying an additional 176 shares during the period. Investment Research Partners LLC increased its stake in Bristol Myers Squibb by 1.4% during the 4th quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company's stock worth $708,000 after buying an additional 179 shares during the period. Finally, REAP Financial Group LLC lifted its holdings in Bristol Myers Squibb by 26.1% during the 4th quarter. REAP Financial Group LLC now owns 879 shares of the biopharmaceutical company's stock worth $47,000 after buying an additional 182 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $63.52 on Friday. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The company has a fifty day simple moving average of $63.61 and a 200-day simple moving average of $60.07. The stock has a market cap of $129.76 billion, a P/E ratio of 13.99, a price-to-earnings-growth ratio of 0.30 and a beta of 0.23. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.64.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb's revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts expect that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.0%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb's payout ratio is currently 55.51%.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Promising multiple myeloma CAR-T results strengthen the pipeline. Bristol Myers said experimental therapy arlocabtagene autoleucel (arlo-cel) met the primary goal of a mid-stage trial in heavily pretreated multiple myeloma patients. The statistically significant and clinically meaningful improvement in overall response rate could support the company’s long-term oncology growth prospects. Bristol Myers’ Cancer Therapy Win Strengthens its Oncology Pipeline
• Positive Sentiment: Growth brands and pipeline progress remain supportive. An analyst review noted that Bristol Myers’ newer growth products and research pipeline are helping drive momentum, contributing to a reported 19.4% year-to-date gain before the latest weakness. BMY Gains 19.4% Year to Date: Should You Buy, Sell or Hold the Stock?
• Neutral Sentiment: Analyst stance remains cautious. Scotiabank maintained a Hold rating, suggesting the positive pipeline developments are not yet sufficient to prompt a more bullish view.
• Neutral Sentiment: Long-term psoriasis study data add information but not an immediate catalyst. Bristol Myers provided an update on an ongoing long-term psoriasis study; the available report did not identify a major change to near-term earnings expectations. Bristol-Myers Squibb’s Long-Term Psoriasis Study Brings Fresh Data for BMY Investors
• Negative Sentiment: Patent-dispute uncertainty weighs on sentiment. RBC said Cytokinetics has an advantage in its patent dispute with Bristol Myers, raising potential legal and competitive concerns. Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says
• Negative Sentiment: Downside hedging and portfolio pressure are visible. Investors purchased about 44,454 BMY put options, roughly 71% above average put volume. Analysts also continue to flag generic pressure on the legacy portfolio, while the stock recently underperformed the broader market.

Insider Activity

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.05% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Piper Sandler started coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued an "overweight" rating for the company. Argus upgraded Bristol Myers Squibb from a "hold" rating to a "buy" rating and set a $75.00 target price for the company in a report on Wednesday, August 5th. Raymond James Financial assumed coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a "strong-buy" rating for the company. Jefferies Financial Group downgraded Bristol Myers Squibb from a "buy" rating to a "hold" rating in a report on Wednesday, August 5th. Finally, Royal Bank Of Canada increased their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a "sector perform" rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $66.33.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.